Partnering
Scientific Collaboration
Accelerating Biomedical Innovation Through Collaborative R&D
At Fazax Group, we believe that the future of biotechnology lies in synchronized, cross-disciplinary collaboration. Within our Science & Innovation ecosystem, partnering means uniting our structural platforms—such as our proprietary mRNA technology and the Depixil complex—with the expertise of independent research institutes, clinical laboratories, and healthcare pioneers.
We are actively seeking alliances to expand our early-stage discovery programs, conduct joint clinical evaluations, and co-develop high-performance bioactive solutions. By combining resources, we translate complex molecular theories into real-world applications that restore homeostasis and enhance human health.
We are actively seeking alliances to expand our early-stage discovery programs, conduct joint clinical evaluations, and co-develop high-performance bioactive solutions. By combining resources, we translate complex molecular theories into real-world applications that restore homeostasis and enhance human health.
Key Areas of Innovation Synergy
- Co-Development & Licensing: Joint development of novel bioactive systems, cellular formulations, and licensing opportunities for our proprietary molecular platforms.
- Clinical Research Partnerships: Collaboration with certified trichology and dermatology clinics to conduct robust, independent trials and gather real-world evidence (RWE).
- Academic Alliances: Partnering with universities and scientific foundations to bridge the gap between fundamental genetic research and scalable health products.
Форма обратной связи
Disclaimer
The information presented on this page was factually accurate as of the date of publication. The Company assumes no obligation to update this information to reflect subsequent scientific or regulatory developments. Readers should not rely upon the information on this page as current or accurate after its publication date.
This section contains "forward-looking statements" regarding our research and development activities, including discussions about potential molecular platforms (such as mRNA), new biological systems for metabolic regulation, and future formulations for existing product lines. These statements reflect the current scientific views of the Company and involve significant risks and uncertainties. Actual results may differ materially from those expressed or implied here due to various factors, including but not limited to: the inherent uncertainties of early-stage biotechnology research; results from ongoing formulation optimization; unexpected regulatory shifts in the classification of bioactive systems; and our ability to maintain proprietary intellectual property protection.
There can be no guarantee that research (such as our mRNA initiatives) will lead to approved medicinal products, or that current developments in metabolic and neuro-modulation will reach the commercial market within any specific timeframe. Furthermore, information regarding our marketed products relates to their status as advanced bioactive cosmetic systems or nutraceuticals designed to support biological homeostasis and physiological functions. These products are not intended to diagnose, treat, cure, or prevent any disease unless expressly stated and approved by relevant national health authorities.
Should underlying scientific assumptions prove incorrect or should unforeseen regulatory risks materialize, actual developmental outcomes may vary materially from those described herein as anticipated or expected.
This section contains "forward-looking statements" regarding our research and development activities, including discussions about potential molecular platforms (such as mRNA), new biological systems for metabolic regulation, and future formulations for existing product lines. These statements reflect the current scientific views of the Company and involve significant risks and uncertainties. Actual results may differ materially from those expressed or implied here due to various factors, including but not limited to: the inherent uncertainties of early-stage biotechnology research; results from ongoing formulation optimization; unexpected regulatory shifts in the classification of bioactive systems; and our ability to maintain proprietary intellectual property protection.
There can be no guarantee that research (such as our mRNA initiatives) will lead to approved medicinal products, or that current developments in metabolic and neuro-modulation will reach the commercial market within any specific timeframe. Furthermore, information regarding our marketed products relates to their status as advanced bioactive cosmetic systems or nutraceuticals designed to support biological homeostasis and physiological functions. These products are not intended to diagnose, treat, cure, or prevent any disease unless expressly stated and approved by relevant national health authorities.
Should underlying scientific assumptions prove incorrect or should unforeseen regulatory risks materialize, actual developmental outcomes may vary materially from those described herein as anticipated or expected.